IQVIA Holdings Inc.
NYSE:IQVMedical - Diagnostics & Research
-$3.13 today
- Market cap
- $42.49B
- Beta
- 1.22
- P/E (TTM)
- 20.4
- EPS (TTM)
- $8.22
Volume 1.40M
Average 1.62M
IQV Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
IQVIA Holdings Inc.NYSE: IQV
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development remains negative
Q2 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.
Context
- Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Research & Development vs competitors
How IQV compares with its peers on the latest reported figures
- IQV's LTM Jun 2026 research & development of $0 is the 5th highest of the 9 companies compared; the peer median is $21.4M.
- Research & development amounts to 0.0% of revenue for IQV, versus a peer median of 5.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $821.92M | +12.5% | +13.8% | 23.8% | |
| LTM Sep 2026 | $327.05M | +12.8% | +25.3% | 21.7% | |
| LTM Mar 2026 | $44.26M | -24.0% | -13.0% | 14.6% | |
| LTM Mar 2026 | $42.8M | +20.1% | +13.3% | 10.2% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
FTREFortrea Holdings Inc. | LTM Jun 2026 | $0 | — | — | 0.0% |
| Peer median (excluding IQV) | $21.4M | +12.7% | +13.6% | 5.1% | |
Competitors are the stored peer set for IQV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 13.87B | 14.41B | 14.98B | 15.41B | 16.31B |
| Cost of Revenue | 9.23B | 9.38B | 9.75B | 10.03B | 10.88B |
| Gross Profit | 4.64B | 5.03B | 5.24B | 5.38B | 5.43B |
| Gross Margin | 33.5% | 34.9% | 35.0% | 34.9% | 33.3% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 1.96B | 2.07B | 2.05B | 1.99B | 1.99B |
| Operating Expenses | 3.25B | 3.23B | 3.26B | 3.17B | 3.25B |
| Depreciation & Amortization | 1.26B | 1.13B | 1.13B | 1.11B | 640M |
| EBITDA | 2.77B | 2.91B | 3.26B | 3.45B | 2.94B |
| EBITDA Margin | 19.9% | 20.2% | 21.7% | 22.4% | 18.0% |
| Operating Income | 1.39B | 1.8B | 1.98B | 2.2B | 2.18B |
| Operating Margin | 10.0% | 12.5% | 13.2% | 14.3% | 13.4% |
| Interest Income | 6M | 13M | 36M | 47M | 45M |
| Interest Expense | 375M | 416M | 672M | 670M | 729M |
| Other Income / Expenses | (259M) | (448M) | (518M) | (533M) | (569M) |
| Income Before Tax | 1.13B | 1.35B | 1.46B | 1.67B | 1.61B |
| Pre-Tax Margin | 8.2% | 9.4% | 9.7% | 10.8% | 9.9% |
| Income Tax Expense | 163M | 260M | 101M | 296M | 252M |
| Net Income | 966M | 1.09B | 1.36B | 1.37B | 1.36B |
| Net Margin | 7.0% | 7.6% | 9.1% | 8.9% | 8.3% |
| EPS (Basic) | 5.05 | 5.82 | 7.39 | 7.57 | 7.91 |
| EPS (Diluted) | 4.95 | 5.72 | 7.29 | 7.49 | 7.84 |
| Weighted Avg Shares | 191.4M | 187.6M | 183.8M | 181.3M | 171.9M |
| Weighted Avg Shares (Diluted) | 195M | 190.6M | 186.3M | 183.4M | 173.5M |
IQVIA Holdings Inc.
NYSE:IQV
Intrinsic Alpha fair value
Locked
Current Price
$257.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.